

OPEN ACCESS

EDITED AND REVIEWED BY
Haitao Wang,
National Cancer Institute (NIH), United States

*CORRESPONDENCE
Nianyong Chen
 n_ychen@hotmail.com

[†]These authors have contributed equally to
this work

RECEIVED 31 May 2024
ACCEPTED 27 June 2024
PUBLISHED 05 July 2024

CITATION

Shen X, Zhong J, He J, Han J and Chen N (2024) Corrigendum: Identification of m6A modification patterns and development of m6A–hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Front. Immunol. 15:1441843.
doi: 10.3389/fimmu.2024.1441843

COPYRIGHT

© 2024 Shen, Zhong, He, Han and Chen. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Identification of m6A modification patterns and development of m6A–hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer

Xi Shen^{1†}, Jianxin Zhong^{2†}, Jinlan He¹, Jiaqi Han¹
and Nianyong Chen^{1*}

¹Department of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, ²Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

KEYWORDS

Triple-negative breast cancer, m6A RNA methylation, m6A-hypoxia signature, tumor microenvironment, immune cell infiltration

A Corrigendum on

[Identification of m6A modification patterns and development of m6A–hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer](#)

By Shen X, Zhong J, He J, Han J and Chen N (2022). *Front. Immunol.* 13:978092.
doi: 10.3389/fimmu.2022.978092.

In the published article, there was an error in [Figure 9F](#) as published. After checking the original paper, the images of [Figure 9F](#) were mistakenly included. The corrected [Figure 9](#) and its caption [Figure 9](#) Nomogram and detection of MHPS gene expression, appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 9

Nomogram and detection of MHPS gene expression. **(A)** Kaplan-Meier analysis of patients with high or low MHPS risk score in METABRIC-TNBC cohort. **(B)** Construction of nomogram scoring system to predict patient survival at 1-, 3- and 5- years. Each clinical factor in the nomogram system corresponds to a score, and all scores are summed to obtain a total point, which can predict the survival rate of patients at 1-, 3- and 5- years. **(C)** Time-dependent ROC for the nomogram, MHPS, tumor size, lymph node in the METABRIC cohort (for predicting 1-, 3-, and 5-years OS). **(D)** Comparison of mRNA expression of hub genes in normal breast and TNBC cell lines. **(E)** Different expression of hub genes in normoxia and hypoxia cultured TNBC cells based on GSE144569 dataset. **(F)** IHC staining to detect protein expression of PIM2 and MKP1 in normal and tumor tissues. Scale bar: 100 μm. (*P < 0.05, **P < 0.01, and ***P < 0.001). ns, not significant.